High doses of topical corticosteroids, commonly prescribed for inflammatory skin conditions, have been associated with an increased risk of osteoporosis and bone fractures. This connection has been demonstrated in a published study conducted by researchers in dermatology and rheumatology. The Journal of the European Academy of Dermatology and Venereology (JEADV) reported these findings.
Researchers analyzed data from about 130 thousand individuals with osteoporosis and 518 thousand healthy controls. The study used information from the Taiwan Health Insurance Database to examine how topical corticosteroid use correlates with bone health outcomes.
The analysis showed that the likelihood of developing osteoporosis within five years rose to 1.22, 1.26, and 1.34 times for those using low, medium, and high doses of topical corticosteroids respectively, compared with individuals not using these medications. A similar pattern emerged for fracture risk. In addition, being younger than 50 and being female were identified as additional risk factors that could influence the association.
The authors advised that clinicians should exercise caution when prescribing topical corticosteroids for inflammatory skin diseases and remain vigilant for potential adverse effects on bone health. It remains important for patients and healthcare providers in Canada and the United States to weigh the benefits of skin symptom control against possible systemic impacts, particularly in long-term therapy or when higher potency regimens are considered.
Researchers emphasize the need for ongoing assessment of bone health in patients undergoing prolonged topical steroid treatment and suggest integrating bone density monitoring and appropriate preventive strategies as part of comprehensive skin disease management.